Zobrazeno 1 - 10
of 468
pro vyhledávání: '"oligoprogression"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Background and purpose The role of local ablative radiotherapy (stereotactic body radiotherapy (SBRT)/stereotactic radiosurgery (SRS)) in the management of metastatic breast cancer (mBC) patients remains unclear. This study aimed to assess t
Externí odkaz:
https://doaj.org/article/9992d226c9df4e4cbd2c321eb4eead18
Autor:
Riccardo Ray Colciago, Chiara Chissotti, Federica Ferrario, Maria Belmonte, Giorgio Purrello, Valeria Faccenda, Denis Panizza, Stefania Canova, Gaia Passarella, Diego Luigi Cortinovis, Stefano Arcangeli
Publikováno v:
Current Oncology, Vol 31, Iss 11, Pp 6840-6852 (2024)
We aimed to evaluate whether progression-directed radiation therapy (PDRT) can prolong the initiation of a subsequent systemic therapy regimen in a cohort of patients with oligoprogressive NSCLC. A retrospective analysis was conducted on NSCLC patien
Externí odkaz:
https://doaj.org/article/471bbc205f554a8597e29baea3c69c91
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) have become the recommended first-line treatment for advanced non-small cell lung cancer (NSCLC) without driver gene mutations. However, data on the failure patterns of first-line ICIs monothera
Externí odkaz:
https://doaj.org/article/20fc6c9067a142739c6f356d6f757710
Autor:
Kana Hashimoto, MD, Daisuke Morinaga, MD, Hajime Asahina, MD, PhD, Mina Ishidoya, MD, Hajime Kikuchi, MD, PhD, Hiroshi Yokouchi, MD, PhD, Toshiyuki Harada, MD, PhD, Osamu Honjo, MD, Ryota Shigaki, MD, Taichi Takashina, MD, PhD, Yuka Fujita, MD, PhD, Mamoru Takahashi, MD, PhD, Yasutaka Kawai, MD, Ryotaro Kida, MD, Kenichiro Ito, MD, Noriaki Sukoh, MD, PhD, Ayumu Takahashi, MD, PhD, Fumihiro Hommura, MD, PhD, Yoshihito Ohhara, MD, PhD, Megumi Furuta, MD, PhD, Satoshi Konno, MD, PhD, Yukio Hosomi, MD, PhD, Satoshi Oizumi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100715- (2024)
Introduction: Oligometastasis and oligoprogression (OP) has not been adequately defined in extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment. Therefore, this multicenter study aimed to investigate the prognostic i
Externí odkaz:
https://doaj.org/article/6a9e9af6ebb84315b50bcf56a349d75d
Autor:
Lauren Julia Brown, M.B.B.S., MClinTRes, FRACP, Julie Ahn, M.B.B.S., Bo Gao, BMedSci M.B.B.S., FRACP, PhD, Harriet Gee, M.B.B.S., DPhil, FRANZCR, Adnan Nagrial, M.B.B.S., FRACP, PhD, Inês Pires da Silva, MD, FRACP, PhD, Eric Hau, BSc (Med), M.B.B.S., Grad Cert (Biostat), FRANZCR, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100695- (2024)
Introduction: The patterns of oligoprogression after first-line immune checkpoint inhibitors (ICIs) for metastatic NSCLC are yet to be well established. An increasing volume of data suggests that directed radiotherapy improves survival outcomes in pa
Externí odkaz:
https://doaj.org/article/ff50c485d92c453b858212d1c3b4e763
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 3, Pp 449-464 (2024)
Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advanced non-small cell lung cancer (NSCLC). Similarly, t
Externí odkaz:
https://doaj.org/article/de47c46bff354bd28eaa4efa93d83c7f
Autor:
Emanuele Chioccola, Mara Caroprese, Christina A. Goodyear, Angela Barillaro, Caterina Oliviero, Stefania Clemente, Chiara Feoli, Luigi Formisano, Antonio Farella, Laura Cella, Manuel Conson, Roberto Pacelli
Publikováno v:
Radiation, Vol 4, Iss 2, Pp 115-124 (2024)
Background: Stereotactic body radiotherapy (SBRT) targeted at metastatic sites of disease progression is emerging as a potential therapeutic approach for managing oligoprogressive prostate cancer. However, a definitive benefit has yet to be demonstra
Externí odkaz:
https://doaj.org/article/6fc61f58850347a397ca551ffe148aa3
Publikováno v:
Current Oncology, Vol 30, Iss 12, Pp 10283-10298 (2023)
Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has been a significant accumulation of clinical data to support the safety and e
Externí odkaz:
https://doaj.org/article/7046ba6749964f33b1302608bfa2632d
Autor:
Sviatoslav Chekhun, Assumpció Lopez-Paradís, Aintzane Urbizu, Teresa Morán, Anabel Mañes, Marc Cucurull, Carlos Martínez-Barenys, Iris Teruel, Gloria Moragas, Enric Carcereny, Ana Maria Muñoz Mármol, Maria Saigí
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 6, Pp 1182-1187 (2023)
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate with a positive impact on overall survival. Nevertheles
Externí odkaz:
https://doaj.org/article/548b16587d6e4b5780c5798654aef425
Autor:
Taketo Kawai, Satoru Taguchi, Keina Nozaki, Naoki Kimura, Takahiro Oshina, Takuya Iwaki, Hotaka Matsui, Aya Niimi, Jun Kamei, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Tomoyuki Kaneko, Subaru Sawayanagi, Hidetsugu Nakayama, Ryogo Minamimoto, Hideomi Yamashita, Hideyo Miyazaki, Tetsuya Fujimura, Tohru Nakagawa, Haruki Kume
Publikováno v:
Prostate International, Vol 11, Iss 4, Pp 239-246 (2023)
Background: In recent years, site-directed therapies (SDTs) targeting progressive lesions in patients with oligometastatic prostate cancer have attracted attention. However, whether they effectively treat oligoprogressive castration-resistant prostat
Externí odkaz:
https://doaj.org/article/6744a01c15f544f59149d86b33600975